Lanean...
PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
Targeting mutant BRAF in patients with melanomas harboring this oncogene has been highly successful as a first-line treatment, but other mutations may affect its efficacy and alter the route of acquired resistance resulting in recurrence and poor prognosis. As an evolving strategy, melanoma treatmen...
Gorde:
| Argitaratua izan da: | NPJ Precis Oncol |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group UK
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8289936/ https://ncbi.nlm.nih.gov/pubmed/34282258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00207-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|